French Trial Tragedy: Dosing Continued After Volunteer Hospitalized
This article was originally published in Scrip
Executive Summary
Data from the Phase I dose-escalation study of Bial's FAAH inhibitor BIA 10-2474 reveal that the first serious adverse reaction occurred on the fifth day after the daily dose had been increased from 20 mg to 50 mg in the multiple-dosing stage of the trial.